Recently, serum biomarkers, including aspartate aminotransferase (AST) to platelet (PLT) ratio index (APRI) [9], Fib-4 (based on age, ALT, AST, and PLT) [10], and γ-glutamyl transpeptidase (GGT) to platelet (GPR) [11], have been reported to effectively and accurately predict significant fibrosis and cirrhosis in patients with CHB and/or hepatitis C. However, these biomarkers were mainly based on patients with hepatitis C or with HCV/HIV coinfection and might produce inconsistent results in CHB patients. The gene discussed is GPT; the disease is hepatitis C virus infection.